Evidence map›Paper›PMID 38652426›Full record

ReviewCurrent oncology reports2024

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape.

Aruni Ghose, Patricia Lapitan, Vedika Apte, Adheesh Ghosh, Abhinav Kandala, Sreejana Basu, Jo Parkes, Sayali D Shinde, Stergios Boussios, Anand Sharma and 7 more

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 6 countries.

Aruni Ghose *Department of Medical Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Patricia Lapitan *British Oncology Network for Undergraduate Societies, London, UK.
Vedika Apte *University College London Medical School, London, UK.
Adheesh GhoshUCL Cancer Institute, University College London, London, UK.
Abhinav KandalaUniversity College London Medical School, London, UK.
Sreejana BasuUCL Cancer Institute, University College London, London, UK.
Jo ParkesImmuno-Oncology Clinical Network, London, UK.
Sayali D ShindeCancer Academic Sciences Unit, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Stergios BoussiosDepartment of Medical Oncology, Medway NHS Foundation Trust, Kent, UK.
Anand SharmaDepartment of Medical Oncology, Mount Vernon Cancer Centre, Mount Vernon and Watford NHS Trust, Watford, UK.
Prantik DasDepartment of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
Nikhil VasdevHertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK.
Sara E RebuzziThe Meet-URO Group, Italian Network for Research in Uro-Oncology, Milan, Italy.
Yüksel ÜrünDepartment of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Akash ManiamDepartment of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK. Akash.Maniam@porthosp.nhs.uk.
Giuseppe L BannaThe Meet-URO Group, Italian Network for Research in Uro-Oncology, Milan, Italy.
University College London · GBRadiotelevisione Italiana (Italy) · ITAnkara University · TRApollo Hospitals · INAssociation for Cancer Surgery · GBBarts Health NHS Trust · GBCRUK Lung Cancer Centre of Excellence · GBLondon Cancer · GBMount Vernon Cancer Centre · GBNational Cancer Centre Singapore · SGUniversity Hospitals of Derby and Burton NHS Foundation Trust · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Kent · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care. RECENT

findingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.

Indexed as

ImmunoconjugatesUrologic NeoplasmsAntibodies, MonoclonalHumansAntibodies, MonoclonalImmunoconjugatesAntibody drug conjugateCancerChemotherapyProstateRenalTesticularUrologyUrothelial

Identifiers

PMID38652426
OpenAlexW4395043336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.